Table 2.
Descriptive characteristics of sarcoma lesions treated with SBRT.
| All Lesions (n = 138) Median [min–max] | |
|---|---|
| Sarcoma histology (%) | |
| Clear cell carcinoma | 3 (2.2) |
| Desmoplastic small round cell tumor | 21 (15.3) |
| Ewing sarcoma | 30 (21.9) |
| Osteosarcoma | 54 (39.4) |
| Paraganglioma | 7 (5.1) |
| Rhabdomyosarcoma | 7 (5.1) |
| Small round blue cell sarcoma | 4 (2.9) |
| Synovial sarcoma | 11 (8.0) |
| Biological equivalent dose (Gy) | 116.70 [66.7–419.3] |
| Pretreatment white blood cell count (103/uL)1 | 5.10 [0.09–15.8] |
| Pretreatment hemoglobin (g/dL) | 12.1 [7.7, 16.8-] |
| Pretreatment hematocrit (%) | 35.6 [23.8–49.3] |
| Pretreatment platelets (103/uL) | 183[11–570] |
| Pretreatment absolute neutrophil count (103/uL) | 3.2 [0.6–14.5] |
| Pretreatment absolute lymphocyte count (103/uL) | 0.60 [0.08–3.8] |
| Pretreatment lactate dehydrogenase units/L) | 211 [125–671] |
| Pretreatment albumin (g/dL) | 4.20 [2.7, 7.8] |
| Pretreatment neutrophil to lymphocyte ratio | 5.3 [0.46, 29.19] |
| Received concurrent therapy (%)2 | 79 (57.2) |
| Surveillance follow up time (months) | 7.7 [0.5–35] |
| Known local recurrences (%)3 | 34 (28.8) |
1Pretreatment complete blood count (CBC) data was charted within 3 months of treating the lesion.
2Concurrent therapy includes any chemotherapy or immunotherapy received at time of treatment.
3Local recurrence was determined by CT, MRI, or PET imaging surveillance. Data is presented as either median [min to max] or as number in category (percent of whole group).